CytomX Therapeutics Third Quarter 2026 Financial Results - CYTOMX THERAPEUTICS INC

Explicit Guidance:

• Cash Runway: Projected cash runway extends into the second half of 2028 based on a $348 million cash/equivalent/investment balance as of September 30, 2026.
• Financial Outlook: No specific future revenue or earnings guidance provided; guidance limited to capital allocation discipline to prioritize Varsetta-M development.

Business-Segment Outlook:

• Varsetta-M (Lead Program):
  • Registrational Study: Aiming to initiate the first potential registrational study in the first half of 2027.
  • Primary Endpoint: Anticipated to be Overall Survival (OS) in a randomized study design.
  • Therapeutic Line: Targeting metastatic Colorectal Cancer (CRC); evaluating both third-line and fourth-line settings, with potential for earlier-line expansion pending combination data.
  • Combination Strategy:
    • Bevacizumab + Chemotherapy: Initiation of a Phase I-II trial expected by the end of 2026 to enroll second-line CRC patients (replacing Irinotecan with Varsetta-M); initial Phase I dose-finding will likely focus on late-stage patients before Phase II expansion.
    • Bevacizumab Monotherapy: Ongoing Phase I; initial clinical data anticipated in the first half of 2027, with potential move to earlier-line CRC evaluation subsequently.
  • Data Updates: Integrated Phase 1 update (including first look at OS) expected in January 2027.
  • Pan-Tumor Expansion: Initiated Phase I cohorts in gastric/gastroesophageal junction, EPCAM-selected pancreatic ductal adenocarcinoma, and biliary tract cancer; planning ~20 patients per tumor type before assessing later-phase options.
• CX801 (Interferon Alpha 2B Program):
  • Indication: Checkpoint refractory melanoma (monotherapy and with Keytruda).
  • Timeline: Initial clinical data from the Phase I melanoma study anticipated in the first half of 2027.

Market and Competitive Outlook:

• Differentiation: Positions Varsetta-M as the only EPCAM-targeting ADC in development (first-in-class); leverages ProBody masking technology to differentiate from competitors targeting other payloads (e.g., CDH17, CEA).
• Competitive Landscape: Acknowledges competitors including App-V, TMAP-A, Merck-Sorona, and Pre-Sem-TCT programs; notes emerging CDH17 ADC data at ESMO.
• Pricing/Volume: Addresses ~35,000 patients in the US with third-line or later CRC; views current standard of care (Bevacizumab/Trilcine/Surufen) as fragmented in third-line+ settings, presenting an opportunity to capture significant market share.
• Safety Benchmark: Management aims to manage Grade 3 diarrhea to 20% or below in combination settings, targeting a favorable safety profile compared to Topo-1 ADCs with higher hematologic toxicity.

Macro / Industry Outlook:

• Regulatory: Awaiting and engaging with regulatory authorities to finalize registrational study design; seeking FDA feedback on trial parameters prior to January data update.
• Industry Trends: Notes ADCs are "coming to colorectal cancer patients," validating the unmet need and urgency for Varsetta-M.
• Economic/Macro: No specific commentary on interest rates, FX, tariffs, or broader macroeconomic conditions impacting the business.

Strategic Initiatives:

• Capital Allocation: Disciplined approach to funding Varsetta-M development (registrational, combinations, and pan-tumor expansion) to maximize value creation.
• Clinical Trial Expansion: Shifting focus from exclusive CRC development to broader EPCAM-expressing GI solid tumors.
• Partnership/Revenue: Recognized $37 million inflow from Regeneron related to expanded target selection in Q3; no new strategic partnerships announced.
• Operational: Maintaining efficient and flexible cost structure to support extended cash runway.

Risks and Headwinds to Outlook:

• Safety Profile: High-grade diarrhea remains the primary safety concern; management of this AE is critical for maximizing dose intensity and efficacy (PFS/OS).
• Clinical Execution: Success of the first registrational study depends on patient population selection, appropriate comparator, and achieving statistical significance in OS.
• Competition: Presence of multiple Phase 3 ADC programs and other emerging targets in the CRC landscape.
• Data Timing: The January update timing is contingent on sufficient patient follow-up and regulatory engagement; delays could impact the first half 2027 registrational initiation.
• General: Standard risks associated with clinical development, including failure to demonstrate efficacy or safety in subsequent cohorts.

Management Tone on the Future:

• Confidence Level: High confidence in the potential of Varsetta-M ("highly productive year," "significant opportunity," "very competitive asset").
• Urgency: Emphasized "sense of urgency" to advance Varsetta-M rapidly due to the unmet need in CRC.
• Hedges: No specific guidance updates or changes vs. prior guidance; tone is forward-looking with standard caution regarding regulatory and clinical uncertainties.

Miscellaneous:

• Target Selection: No specific guidance provided on the final selected dose for Phase III; decision expected as part of the January update.
• Dosing Strategy: Investigating Ideal Body Weight (AIBW) adjusted dosing and prophylaxis for GI toxicity management in future studies; likely implementation in combination trials.